BioRender Valuation, Funding & Investors

BioRender is valued at $900M as of April 2023.

Last BioRender valuation

$900M

Series A · Apr 2023

Last BioRender funding round

$15M

Series A · Apr 2023

Cumulative funding BioRender raised

$17M

across 2 funding rounds

Key investors in BioRender

  • Y Combinator
  • Liquid 2 Ventures
  • FundersClub
  • Refactor
  • Brad Flora
  • Zeno Partners

BioRender Overview

About BioRender

BioRender is a Toronto-headquartered web platform enabling scientists in pharmaceuticals and life sciences to create publication-ready figures and illustrations. Launched in 2018, it hosts over 50,000 customizable icons across biology, chemistry, and medicine, used by more than 10 million researchers at institutions like Harvard, Pfizer, and Novartis. The tool supports collaborative editing, exports in vector formats for journals such as Nature and Cell, and integrates with lab notebooks, streamlining communication with consistent visual standards.


Founded

2017

HQ

CanadaToronto

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Valuation

$900M (Apr 2023)

BioRender Valuation

BioRender is currently valued at $900M, based on its Series A in April 2023.

The $15M round was led by Y Combinator.

BioRender valuation by funding round

BioRender valuation by funding round
DateStageValuation
Apr 2023Series A$900M

BioRender Funding History

BioRender has raised a total of $17M across 2 funding rounds.

BioRender's first fundraising round was a $2M seed round in January 2018. The most recent completed round was a $15M Series A in April 2023.

BioRender funding rounds

BioRender funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Apr 2023Series AY Combinator (lead)$15M$900MBioRender is a software platform that enables scientists to create and share publication-quality scientific figures and illustrations. Founded in 2017 by Shiz Aoki, Katya Shteyn, and Ryan Marien, the company was a Y Combinator Winter 2018 graduate. The platform serves researchers across over 100 countries and has built a library of icons and templates across more than 30 fields of biology. Most recently, in 2024, the company announced a $900 million valuation following an investment from Dimension Capital, positioning it as a unicorn-valued company. As a profitable company at that time, BioRender offered equity liquidity to over 100 employees, underscoring the company's strong financial position and commitment to employee ownership. The platform has become deeply embedded in scientific workflows, used by PhD students creating research posters, pharma teams developing mechanism-of-action visualizations, and researchers preparing grant applications and publications.
Jan 2018SeedY Combinator (lead); Liquid 2 Ventures; Refactor; Zeno Partners; FundersClub; Brad Flora$2M--

Who has invested in BioRender?

6 investors have backed BioRender across its funding rounds, including Y Combinator, Liquid 2 Ventures, FundersClub, Refactor, Brad Flora and Zeno Partners.

Lead investors include Y Combinator.


BioRender Investors

Investors in BioRender by funding rounds participated
InvestorHQRoundsRoleFirst check
Y CombinatorUnited StatesSan Francisco, CA2LeadJan 2018
Liquid 2 VenturesUnited StatesSan Francisco, CA1ParticipantJan 2018
RefactorUnited StatesSan Francisco, CA1ParticipantJan 2018
Zeno PartnersUnited StatesSan Francisco, CA1ParticipantJan 2018

This data is available for Pro users. Sign up to see all 6 BioRender investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

BioRender Competitors

BioRender competitors include listed companies like Forward Industries and Lectra, and private ones like Collate, DNAnexus, David AI and Astromech.

Public and private companies comparable to BioRender
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
CollateUnited StatesSan Francisco, CAPrivate--$1B-
DNAnexusUnited StatesSan Francisco, CAPrivate--$600M-
David AIUnited StatesSan Francisco, CAPrivate--$500M-
Forward IndustriesUnited StatesUnited StatesPublicly listed$18M($169M)$459M10.1x
AstromechUnited StatesUnited StatesPrivate--$3.8B-
LectraFranceFrancePublicly listed$584M$91M$890M1.7x

BioRender Public Comps

BioRender is still privately-owned, but its public comps include Lectra, Bide Pharmatech Co, CryoPort, Smarter Microelectronics, Nagarro, Mensch und Maschine, SEEGENE, ZUKEN, Addnode Group and OmniAb.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Lectra$584M$91M1.7x1.7x11.0x11.1x
Bide Pharmatech Co$197M$33M3.8x3.5x22.7x-
CryoPort$176M($2M)4.2x3.9x(349.1x)(974.7x)
Smarter Microelectronics$120M($31M)7.7x7.8x(30.2x)(31.1x)
Nagarro$1.2B$134M1.2x1.2x10.2x8.0x
Mensch und Maschine$275M$68M2.7x2.6x10.9x9.8x
SEEGENE$345M$85M2.3x2.1x9.2x7.7x
ZUKEN$277M$51M1.6x1.7x8.9x-

This data is available for Pro users. Sign up to see all BioRender competitors and their valuation data.

Start Free Trial

Common questions about BioRender

When was BioRender founded?BioRender was founded in 2017.
Where is BioRender headquartered?BioRender is headquartered in Toronto, Canada.
Is BioRender publicly listed?No, BioRender is a private, VC-backed company.
What is BioRender's valuation?BioRender was last valued at $900M in its Series A in April 2023.
How much funding has BioRender raised?BioRender has raised $17M across 2 funding rounds.
What was BioRender's last funding round?BioRender's last funding round was a $15M Series A in April 2023, led by Y Combinator.
Who are BioRender's investors?BioRender's investors include Y Combinator, Liquid 2 Ventures, Refactor, Zeno Partners, FundersClub and Brad Flora.
Which companies are comparable to BioRender?Companies comparable to BioRender include Collate, DNAnexus, David AI, Forward Industries, Astromech and Lectra.

See companies similar to BioRender

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial